<DOC>
	<DOCNO>NCT00569036</DOCNO>
	<brief_summary>This Phase 1 dose escalation study determine safety , tolerability , pharmacokinetics , pharmacodynamics preliminary anti-tumor activity BMS-754807 patient advance metastatic solid tumor . In addition , study expect identify recommend dose dose range BMS-754807 Phase 2 study</brief_summary>
	<brief_title>Multiple Dose Study In Cancer Patients : Safety Tolerability BMS-754807 Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Subjects advance metastatic solid tumor standard care ineffective inappropriate ECOG performance status 01 least 4 week surgery last dose prior anticancer therapy symptomatic brain metastasis disorder dysregulation glucose homeostasis { e.g . diabetes ) uncontrolled significant cardiovascular disease inadequate bone marrow , liver kidney function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Advanced Metastatic Solid Tumors Neoplasms</keyword>
</DOC>